Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Ontology-based Precision Vaccinology for Deep Mechanism Understanding and Precision Vaccine Development

Author(s): Jiangan Xie*, Wenrui Zi, Zhangyong Li and Yongqun He*

Volume 27, Issue 7, 2021

Published on: 24 November, 2020

Page: [900 - 910] Pages: 11

DOI: 10.2174/1381612826666201125112131

Price: $65

Abstract

Vaccination is one of the most important innovations in human history. It has also become a hot research area in a new application - the development of new vaccines against non-infectious diseases such as cancers. However, effective and safe vaccines still do not exist for many diseases, and where vaccines exist, their protective immune mechanisms are often unclear. Although licensed vaccines are generally safe, various adverse events, and sometimes severe adverse events, still exist for a small population. Precision medicine tailors medical intervention to the personal characteristics of individual patients or sub-populations of individuals with similar immunity-related characteristics. Precision vaccinology is a new strategy that applies precision medicine to the development, administration, and post-administration analysis of vaccines. Several conditions contribute to make this the right time to embark on the development of precision vaccinology. First, the increased level of research in vaccinology has generated voluminous “big data” repositories of vaccinology data. Secondly, new technologies such as multi-omics and immunoinformatics bring new methods for investigating vaccines and immunology. Finally, the advent of AI and machine learning software now makes possible the marriage of Big Data to the development of new vaccines in ways not possible before. However, something is missing in this marriage, and that is a common language that facilitates the correlation, analysis, and reporting nomenclature for the field of vaccinology. Solving this bioinformatics problem is the domain of applied biomedical ontology. Ontology in the informatics field is human- and machine-interpretable representation of entities and the relations among entities in a specific domain. The Vaccine Ontology (VO) and Ontology of Vaccine Adverse Events (OVAE) have been developed to support the standard representation of vaccines, vaccine components, vaccinations, host responses, and vaccine adverse events. Many other biomedical ontologies have also been developed and can be applied in vaccine research. Here, we review the current status of precision vaccinology and how ontological development will enhance this field, and propose an ontology-based precision vaccinology strategy to support precision vaccine research and development.

Keywords: Vaccine, precision vaccinology, precision vaccine, ontology, adverse event, vaccine ontology, ontology of adverse events.

« Previous Next »
[1]
André FE. Vaccinology: past achievements, present roadblocks and future promises. Vaccine 2003; 21(7-8): 593-5.
[http://dx.doi.org/10.1016/S0264-410X(02)00702-8] [PMID: 12531323]
[2]
Delany I, Rappuoli R, De Gregorio E. Vaccines for the 21st century. EMBO Mol Med 2014; 6(6): 708-20.
[http://dx.doi.org/10.1002/emmm.201403876] [PMID: 24803000]
[3]
Henderson DA. The eradication of smallpox--an overview of the past, present, and future. Vaccine 2011; 29(Suppl. 4): D7-9.
[http://dx.doi.org/10.1016/j.vaccine.2011.06.080] [PMID: 22188929]
[4]
Wright PF, Kim-Farley RJ, de Quadros CA, et al. Strategies for the global eradication of poliomyelitis by the year 2000. N Engl J Med 1991; 325(25): 1774-9.
[http://dx.doi.org/10.1056/NEJM199112193252504] [PMID: 1719418]
[5]
Orenstein WA, Cairns L, Hinman A, Nkowane B, Olivé JM, Reingold AL. Measles and rubella global strategic plan 2012-2020 midterm review report: background and summary. Vaccine 2018; 36(Suppl. 1): A35-42.
[http://dx.doi.org/10.1016/j.vaccine.2017.10.065] [PMID: 29307368]
[6]
Pappalardo F, Chiacchio F, Motta S. Cancer vaccines: state of the art of the computational modeling approaches. BioMed Res Int 2013; 2013106407
[http://dx.doi.org/10.1155/2013/106407] [PMID: 23484073]
[7]
Marciani DJ. Effects of immunomodulators on the response induced by vaccines against autoimmune diseases. Autoimmunity 2017; 50(7): 393-402.
[http://dx.doi.org/10.1080/08916934.2017.1373766] [PMID: 28906131]
[8]
Anderson RP, Jabri B. Vaccine against autoimmune disease: antigen-specific immunotherapy. Curr Opin Immunol 2013; 25(3): 410-7.
[http://dx.doi.org/10.1016/j.coi.2013.02.004] [PMID: 23478068]
[9]
Poland GA, Ovsyannikova IG, Kennedy RB. Personalized vaccinology: A review. Vaccine 2018; 36(36): 5350-7.
[http://dx.doi.org/10.1016/j.vaccine.2017.07.062] [PMID: 28774561]
[10]
Poland GA, Kennedy RB, Ovsyannikova IG. Vaccinomics and personalized vaccinology: is science leading us toward a new path of directed vaccine development and discovery? PLoS Pathog 2011; 7(12)e1002344
[http://dx.doi.org/10.1371/journal.ppat.1002344] [PMID: 22241978]
[11]
Engler RJ, Nelson MR, Klote MM, et al. Walter Reed Health Care System Influenza Vaccine Consortium. Half- vs full-dose trivalent inactivated influenza vaccine (2004-2005): age, dose, and sex effects on immune responses. Arch Intern Med 2008; 168(22): 2405-14.
[http://dx.doi.org/10.1001/archinternmed.2008.513] [PMID: 19064822]
[12]
Klein SL, Hodgson A, Robinson DP. Mechanisms of sex disparities in influenza pathogenesis. J Leukoc Biol 2012; 92(1): 67-73.
[http://dx.doi.org/10.1189/jlb.0811427] [PMID: 22131346]
[13]
Beery AK, Zucker I. Sex bias in neuroscience and biomedical research. Neurosci Biobehav Rev 2011; 35(3): 565-72.
[http://dx.doi.org/10.1016/j.neubiorev.2010.07.002] [PMID: 20620164]
[14]
König IR, Fuchs O, Hansen G, von Mutius E, Kopp MV. What is precision medicine? Eur Respir J 2017; 50(4): 50.
[http://dx.doi.org/10.1183/13993003.00391-2017] [PMID: 29051268]
[15]
Council NR. Toward precision medicine: building a knowledge network for biomedical research and a new taxonomy of disease. National Academies Press 2011.
[16]
Ginsburg GS, Phillips KA. Precision medicine: from science to value. Health Aff (Millwood) 2018; 37(5): 694-701.
[http://dx.doi.org/10.1377/hlthaff.2017.1624] [PMID: 29733705]
[17]
Ong E, Wang LL, Schaub J, et al. Kidney precision medicine project. modelling kidney disease using ontology: insights from the kidney precision medicine project. Nat Rev Nephrol 2020; 16(11): 686-96.
[http://dx.doi.org/10.1038/s41581-020-00335-w] [PMID: 32939051]
[18]
Borriello F, van Haren SD, Levy O. First international precision vaccines conference: multidisciplinary approaches to next-generation vaccines. MSphere 2018; 3(4)
[19]
Poland GA, Ovsyannikova IG, Jacobson RM. Personalized vaccines: the emerging field of vaccinomics. Expert Opin Biol Ther 2008; 8(11): 1659-67.
[http://dx.doi.org/10.1517/14712598.8.11.1659] [PMID: 18847302]
[20]
Haralambieva IH, Kennedy RB, Ovsyannikova IG, Schaid DJ, Poland GA. Current perspectives in assessing humoral immunity after measles vaccination. Expert Rev Vaccines 2019; 18(1): 75-87.
[http://dx.doi.org/10.1080/14760584.2019.1559063] [PMID: 30585753]
[21]
Hagan T, Nakaya HI, Subramaniam S, Pulendran B. Systems vaccinology: Enabling rational vaccine design with systems biological approaches. Vaccine 2015; 33(40): 5294-301.
[http://dx.doi.org/10.1016/j.vaccine.2015.03.072] [PMID: 25858860]
[22]
Raeven RHM, van Riet E, Meiring HD, Metz B, Kersten GFA. Systems vaccinology and big data in the vaccine development chain. Immunology 2019; 156(1): 33-46.
[http://dx.doi.org/10.1111/imm.13012] [PMID: 30317555]
[23]
Hulsen T, Jamuar SS, Moody AR, et al. From big data to precision medicine. Front Med (Lausanne) 2019; 6: 34.
[http://dx.doi.org/10.3389/fmed.2019.00034] [PMID: 30881956]
[24]
Stevens R, Goble CA, Bechhofer S. Ontology-based knowledge representation for bioinformatics. Brief Bioinform 2000; 1(4): 398-414.
[http://dx.doi.org/10.1093/bib/1.4.398] [PMID: 11465057]
[25]
Barros M, Couto FM. Knowledge representation and management: a linked data perspective. Yearb Med Inform 2016; (1): 178-83.
[http://dx.doi.org/10.15265/IY-2016-022] [PMID: 27830248]
[26]
Xie J, Zhao L, Zhou S, He Y. Statistical and ontological analysis of adverse events associated with monovalent and combination vaccines against Hepatitis A and B diseases. Sci Rep 2016; 6: 34318.
[http://dx.doi.org/10.1038/srep34318] [PMID: 27694888]
[27]
Nural MV, Cotterell ME, Peng H, Xie R, Ma P, Miller JA. Automated predictive big data analytics using ontology based semantics. Int J Big Data 2015; 2(2): 43-56.
[http://dx.doi.org/10.29268/stbd.2015.2.2.4] [PMID: 29657954]
[28]
Amith M, He Z, Bian J, Lossio-Ventura JA, Tao C. Assessing the practice of biomedical ontology evaluation: Gaps and opportunities. J Biomed Inform 2018; 80: 1-13.
[http://dx.doi.org/10.1016/j.jbi.2018.02.010] [PMID: 29462669]
[29]
Haendel MA, Chute CG, Robinson PN. Classification, ontology, and precision medicine. N Engl J Med 2018; 379(15): 1452-62.
[http://dx.doi.org/10.1056/NEJMra1615014] [PMID: 30304648]
[30]
Liyanage H, Williams J, Byford R, Stergioulas L, de Lusignan S. Ontologies in big health data analytics: application to routine clinical data. Stud Health Technol Inform 2018; 255: 65-9.
[PMID: 30306908]
[31]
He Y, Ong E, Schaub J, et al. OPMI: the Ontology of Precision Medicine and Investigation and its support for clinical data and metadata representation and analysis. The 10th International Conference on Biomedical Ontology (ICBO-2019): Buffalo, NY, USA
[32]
Kennedy RB, Ovsyannikova IG, Lambert ND, Haralambieva IH, Poland GA. The personal touch: strategies toward personalized vaccines and predicting immune responses to them. Expert Rev Vaccines 2014; 13(5): 657-69.
[http://dx.doi.org/10.1586/14760584.2014.905744] [PMID: 24702429]
[33]
Ludwig S, Zarbock A. Coronaviruses and SARS-CoV-2: A Brief Overview. Anesth Analg 2020; 131(1): 93-6.
[http://dx.doi.org/10.1213/ANE.0000000000004845] [PMID: 32243297]
[34]
Poland GA, Ovsyannikova IG, Kennedy RB, Haralambieva IH, Jacobson RM. Vaccinomics and a new paradigm for the development of preventive vaccines against viral infections. OMICS 2011; 15(9): 625-36.
[http://dx.doi.org/10.1089/omi.2011.0032] [PMID: 21732819]
[35]
Barreto ML, Pilger D, Pereira SM, et al. Causes of variation in BCG vaccine efficacy: examining evidence from the BCG REVAC cluster randomized trial to explore the masking and the blocking hypotheses. Vaccine 2014; 32(30): 3759-64.
[http://dx.doi.org/10.1016/j.vaccine.2014.05.042] [PMID: 24852722]
[36]
Angelidou A, Diray-Arce J, Conti MG, et al. BCG as a case study for precision vaccine development: lessons from vaccine heterogeneity, trained immunity, and immune ontogeny. Front Microbiol 2020; 11: 332.
[http://dx.doi.org/10.3389/fmicb.2020.00332] [PMID: 32218774]
[37]
Curtis N, Sparrow A, Ghebreyesus TA, Netea MG. Considering BCG vaccination to reduce the impact of COVID-19. Lancet 2020; 395(10236): 1545-6.
[http://dx.doi.org/10.1016/S0140-6736(20)31025-4] [PMID: 32359402]
[38]
Kennedy RB, Poland GA. The top five “game changers” in vaccinology: toward rational and directed vaccine development. OMICS 2011; 15(9): 533-7.
[http://dx.doi.org/10.1089/omi.2011.0012] [PMID: 21815811]
[39]
Klein SL, Poland GA. Personalized vaccinology: one size and dose might not fit both sexes. Vaccine 2013; 31(23): 2599-600.
[http://dx.doi.org/10.1016/j.vaccine.2013.02.070] [PMID: 23579257]
[40]
Couch RB, Winokur P, Brady R, et al. Safety and immunogenicity of a high dosage trivalent influenza vaccine among elderly subjects. Vaccine 2007; 25(44): 7656-63.
[http://dx.doi.org/10.1016/j.vaccine.2007.08.042] [PMID: 17913310]
[41]
Furman D, Hejblum BP, Simon N, et al. Systems analysis of sex differences reveals an immunosuppressive role for testosterone in the response to influenza vaccination. Proc Natl Acad Sci USA 2014; 111(2): 869-74.
[http://dx.doi.org/10.1073/pnas.1321060111] [PMID: 24367114]
[42]
Kennedy RB, Ovsyannikova IG, Pankratz VS, et al. Gender effects on humoral immune responses to smallpox vaccine. Vaccine 2009; 27(25-26): 3319-23.
[http://dx.doi.org/10.1016/j.vaccine.2009.01.086] [PMID: 19200827]
[43]
Veit O, Niedrig M, Chapuis-Taillard C, et al. Swiss HIV Cohort Study. Immunogenicity and safety of yellow fever vaccination for 102 HIV-infected patients. Clin Infect Dis 2009; 48(5): 659-66.
[http://dx.doi.org/10.1086/597006] [PMID: 19191654]
[44]
Kanesa-Thasan N, Sun W, Ludwig GV, et al. Atypical antibody responses in dengue vaccine recipients. Am J Trop Med Hyg 2003; 69(6)(Suppl.): 32-8.
[http://dx.doi.org/10.4269/ajtmh.2003.69.32] [PMID: 14740953]
[45]
Gomez CR, Boehmer ED, Kovacs EJ. The aging innate immune system. Curr Opin Immunol 2005; 17(5): 457-62.
[http://dx.doi.org/10.1016/j.coi.2005.07.013] [PMID: 16084711]
[46]
Allman D, Miller JP. The aging of early B-cell precursors. Immunol Rev 2005; 205: 18-29.
[http://dx.doi.org/10.1111/j.0105-2896.2005.00269.x] [PMID: 15882342]
[47]
Weber DJ, Rutala WA, Samsa GP, Santimaw JE, Lemon SM. Obesity as a predictor of poor antibody response to hepatitis B plasma vaccine. JAMA 1985; 254(22): 3187-9.
[http://dx.doi.org/10.1001/jama.1985.03360220053027] [PMID: 2933532]
[48]
Talbot HK, Coleman LA, Crimin K, et al. Association between obesity and vulnerability and serologic response to influenza vaccination in older adults. Vaccine 2012; 30(26): 3937-43.
[http://dx.doi.org/10.1016/j.vaccine.2012.03.071] [PMID: 22484350]
[49]
Gallaher WR. Towards a sane and rational approach to management of Influenza H1N1 2009. Virol J 2009; 6: 51.
[http://dx.doi.org/10.1186/1743-422X-6-51] [PMID: 19422701]
[50]
Sheridan PA, Paich HA, Handy J, et al. Obesity is associated with impaired immune response to influenza vaccination in humans. Int J Obes 2012; 36(8): 1072-7.
[http://dx.doi.org/10.1038/ijo.2011.208] [PMID: 22024641]
[51]
Camilloni B, Basileo M, Valente S, Nunzi E, Iorio AM. Immunogenicity of intramuscular MF59-adjuvanted and intradermal administered influenza enhanced vaccines in subjects aged over 60: A literature review. Hum Vaccin Immunother 2015; 11(3): 553-63.
[http://dx.doi.org/10.1080/21645515.2015.1011562] [PMID: 25714138]
[52]
Whitaker JA, Ovsyannikova IG, Poland GA. Adversomics: a new paradigm for vaccine safety and design. Expert Rev Vaccines 2015; 14(7): 935-47.
[http://dx.doi.org/10.1586/14760584.2015.1038249] [PMID: 25937189]
[53]
Poland GA, Ovsyannikova IG, Jacobson RM. Adversomics: the emerging field of vaccine adverse event immunogenetics. Pediatr Infect Dis J 2009; 28(5): 431-2.
[http://dx.doi.org/10.1097/INF.0b013e3181a6a511] [PMID: 19395950]
[54]
Dubé E, Laberge C, Guay M, Bramadat P, Roy R, Bettinger J. Vaccine hesitancy: an overview. Hum Vaccin Immunother 2013; 9(8): 1763-73.
[http://dx.doi.org/10.4161/hv.24657] [PMID: 23584253]
[55]
Black FL, Hierholzer W, Woodall JP, Pinhiero F. Intensified reactions to measles vaccine in unexposed populations of American Indians. J Infect Dis 1971; 124(3): 306-17.
[http://dx.doi.org/10.1093/infdis/124.3.306] [PMID: 4947190]
[56]
Siber GR, Santosham M, Reid GR, et al. Impaired antibody response to Haemophilus influenzae type b polysaccharide and low IgG2 and IgG4 concentrations in Apache children. N Engl J Med 1990; 323(20): 1387-92.
[http://dx.doi.org/10.1056/NEJM199011153232005] [PMID: 2233905]
[57]
Goldblatt D, Scadding GK, Lund VJ, Wade AM, Turner MW, Pandey JP. Association of Gm allotypes with the antibody response to the outer membrane proteins of a common upper respiratory tract organism, Moraxella catarrhalis. J Immunol 1994; 153(11): 5316-20.
[PMID: 7963583]
[58]
Pondo T, Rose CE Jr, Martin SW, et al. Evaluation of sex, race, body mass index and pre-vaccination serum progesterone levels and post-vaccination serum anti-anthrax protective immunoglobulin G on injection site adverse events following anthrax vaccine adsorbed (AVA) in the CDC AVA human clinical trial. Vaccine 2014; 32(28): 3548-54.
[http://dx.doi.org/10.1016/j.vaccine.2014.04.025] [PMID: 24768633]
[59]
Xie J, Codd C, Mo K, He Y. Differential adverse event profiles associated with BCG as a preventive tuberculosis vaccine or therapeutic bladder cancer vaccine identified by comparative ontology-based vaers and literature meta-analysis. PLoS One 2016; 11(10)e0164792
[http://dx.doi.org/10.1371/journal.pone.0164792] [PMID: 27749923]
[60]
Croce E, Hatz C, Jonker EF, Visser LG, Jaeger VK, Bühler S. Safety of live vaccinations on immunosuppressive therapy in patients with immune-mediated inflammatory diseases, solid organ transplantation or after bone-marrow transplantation - A systematic review of randomized trials, observational studies and case reports. Vaccine 2017; 35(9): 1216-26.
[http://dx.doi.org/10.1016/j.vaccine.2017.01.048] [PMID: 28162821]
[61]
Verbeek NE, Jansen FE, Vermeer-de Bondt PE, et al. Etiologies for seizures around the time of vaccination. Pediatrics 2014; 134(4): 658-66.
[http://dx.doi.org/10.1542/peds.2014-0690] [PMID: 25225143]
[62]
Reif DM, McKinney BA, Motsinger AA, et al. Genetic basis for adverse events after smallpox vaccination. J Infect Dis 2008; 198(1): 16-22.
[http://dx.doi.org/10.1086/588670] [PMID: 18454680]
[63]
Bae HG, Domingo C, Tenorio A, et al. Immune response during adverse events after 17D-derived yellow fever vaccination in Europe. J Infect Dis 2008; 197(11): 1577-84.
[http://dx.doi.org/10.1086/587844] [PMID: 18419548]
[64]
Nyati KK, Prasad KN, Verma A, et al. Association of TLR4 Asp299Gly and Thr399Ile polymorphisms with Guillain-Barré syndrome in Northern Indian population. J Neuroimmunol 2010; 218(1-2): 116-9.
[http://dx.doi.org/10.1016/j.jneuroim.2009.10.018] [PMID: 19913922]
[65]
Spencer JP, Trondsen Pawlowski RH, Thomas S. Vaccine adverse events: separating myth from reality. Am Fam Physician 2017; 95(12): 786-94.
[PMID: 28671426]
[66]
Nakayama T. Causal relationship between immunological responses and adverse reactions following vaccination. Vaccine 2019; 37(2): 366-71.
[http://dx.doi.org/10.1016/j.vaccine.2018.11.045] [PMID: 30503656]
[67]
Pellegrino P, Falvella FS, Perrone V, et al. The first steps towards the era of personalised vaccinology: predicting adverse reactions. Pharmacogenomics J 2015; 15(3): 284-7.
[http://dx.doi.org/10.1038/tpj.2014.57] [PMID: 25287071]
[68]
Haber P, Patel M, Pan Y, et al. Intussusception after rotavirus vaccines reported to US VAERS, 2006-2012. Pediatrics 2013; 131(6): 1042-9.
[http://dx.doi.org/10.1542/peds.2012-2554] [PMID: 23669521]
[69]
Weintraub ES, Baggs J, Duffy J, et al. Risk of intussusception after monovalent rotavirus vaccination. N Engl J Med 2014; 370(6): 513-9.
[http://dx.doi.org/10.1056/NEJMoa1311738] [PMID: 24422678]
[70]
Cale CM, Klein NJ. The link between rotavirus vaccination and intussusception: implications for vaccine strategies. Gut 2002; 50(1): 11-2.
[http://dx.doi.org/10.1136/gut.50.1.11] [PMID: 11772959]
[71]
Lindsey NP, Schroeder BA, Miller ER, et al. Adverse event reports following yellow fever vaccination. Vaccine 2008; 26(48): 6077-82.
[http://dx.doi.org/10.1016/j.vaccine.2008.09.009] [PMID: 18809449]
[72]
Shohat T, Green MS, Nakar O, et al. Gender differences in the reactogenicity of measles-mumps-rubella vaccine. Isr Med Assoc J 2000; 2(3): 192-5.
[PMID: 10774264]
[73]
Beyer WE, Palache AM, Kerstens R, Masurel N. Gender differences in local and systemic reactions to inactivated influenza vaccine, established by a meta-analysis of fourteen independent studies. Eur J Clin Microbiol Infect Dis 1996; 15(1): 65-70.
[http://dx.doi.org/10.1007/BF01586187] [PMID: 8641306]
[74]
Herr HW, Morales A. History of bacillus Calmette-Guerin and bladder cancer: an immunotherapy success story. J Urol 2008; 179(1): 53-6.
[http://dx.doi.org/10.1016/j.juro.2007.08.122] [PMID: 17997439]
[75]
Cheever MA, Higano CS. PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. Clin Cancer Res 2011; 17(11): 3520-6.
[http://dx.doi.org/10.1158/1078-0432.CCR-10-3126] [PMID: 21471425]
[76]
Desrichard A, Snyder A, Chan TA. Cancer Neoantigens and Applications for Immunotherapy. Clin Cancer Res 2016; 22(4): 807-12.
[http://dx.doi.org/10.1158/1078-0432.CCR-14-3175] [PMID: 26515495]
[77]
Christofi T, Baritaki S, Falzone L, Libra M, Zaravinos A. Current perspectives in cancer immunotherapy. Cancers (Basel) 2019; 11(10): 11.
[http://dx.doi.org/10.3390/cancers11101472] [PMID: 31575023]
[78]
Harper DM, DeMars LR. HPV vaccines - A review of the first decade. Gynecol Oncol 2017; 146(1): 196-204.
[http://dx.doi.org/10.1016/j.ygyno.2017.04.004] [PMID: 28442134]
[79]
Blumberg BS. The curiosities of hepatitis B virus: prevention, sex ratio, and demography. Proc Am Thorac Soc 2006; 3(1): 14-20.
[http://dx.doi.org/10.1513/pats.200510-108JH] [PMID: 16493147]
[80]
Schietinger A, Philip M, Schreiber H. Specificity in cancer immunotherapy. Semin Immunol 2008; 20(5): 276-85.
[http://dx.doi.org/10.1016/j.smim.2008.07.001] [PMID: 18684640]
[81]
Palena C, Abrams SI, Schlom J, Hodge JW. Cancer vaccines: preclinical studies and novel strategies. Adv Cancer Res 2006; 95: 115-45.
[http://dx.doi.org/10.1016/S0065-230X(06)95004-0] [PMID: 16860657]
[82]
Lollini PL, Cavallo F, Nanni P, Forni G. Vaccines for tumour prevention. Nat Rev Cancer 2006; 6(3): 204-16.
[http://dx.doi.org/10.1038/nrc1815] [PMID: 16498443]
[83]
Weller M, Roth P, Preusser M, et al. Vaccine-based immunotherapeutic approaches to gliomas and beyond. Nat Rev Neurol 2017; 13(6): 363-74.
[http://dx.doi.org/10.1038/nrneurol.2017.64] [PMID: 28497804]
[84]
Novak P, Kontsekova E, Zilka N, Novak M. Ten years of tau-targeted immunotherapy: the path walked and the roads ahead. Front Neurosci 2018; 12: 798.
[http://dx.doi.org/10.3389/fnins.2018.00798] [PMID: 30450030]
[85]
Bondi MW, Edmonds EC, Salmon DP. Alzheimer’s disease: past, present, and future. J Int Neuropsychol Soc 2017; 23(9-10): 818-31.
[http://dx.doi.org/10.1017/S135561771700100X] [PMID: 29198280]
[86]
Guo T, Noble W, Hanger DP. Roles of tau protein in health and disease. Acta Neuropathol 2017; 133(5): 665-704.
[http://dx.doi.org/10.1007/s00401-017-1707-9] [PMID: 28386764]
[87]
Brunello CA, Merezhko M, Uronen RL, Huttunen HJ. Mechanisms of secretion and spreading of pathological tau protein. Cell Mol Life Sci 2020; 77(9): 1721-44.
[http://dx.doi.org/10.1007/s00018-019-03349-1] [PMID: 31667556]
[88]
Avila J, Lucas JJ, Perez M, Hernandez F. Role of tau protein in both physiological and pathological conditions. Physiol Rev 2004; 84(2): 361-84.
[http://dx.doi.org/10.1152/physrev.00024.2003] [PMID: 15044677]
[89]
Hovakimyan A, Antonyan T, Shabestari SK, et al. A MultiTEP platform-based epitope vaccine targeting the phosphatase activating domain (PAD) of tau: therapeutic efficacy in PS19 mice. Sci Rep 2019; 9(1): 15455.
[http://dx.doi.org/10.1038/s41598-019-51809-2] [PMID: 31664089]
[90]
Ceyzériat K, Zilli T, Millet P, Frisoni GB, Garibotto V, Tournier BB. Learning from the past: a review of clinical trials targeting amyloid, tau and neuroinflammation in Alzheimer’s disease. Curr Alzheimer Res 2020; 17(2): 112-25.
[http://dx.doi.org/10.2174/1567205017666200304085513] [PMID: 32129164]
[91]
Fink K. Can we improve vaccine efficacy by targeting T and B cell repertoire convergence? Front Immunol 2019; 10: 110.
[http://dx.doi.org/10.3389/fimmu.2019.00110] [PMID: 30814993]
[92]
Miyasaka A, Yoshida Y, Wang T, Takikawa Y. Next-generation sequencing analysis of the human T-cell and B-cell receptor repertoire diversity before and after hepatitis B vaccination. Hum Vaccin Immunother 2019; 15(11): 2738-53.
[http://dx.doi.org/10.1080/21645515.2019.1600987] [PMID: 30945971]
[93]
Rappuoli R. Reverse vaccinology. Curr Opin Microbiol 2000; 3(5): 445-50.
[http://dx.doi.org/10.1016/S1369-5274(00)00119-3] [PMID: 11050440]
[94]
Sette A, Rappuoli R. Reverse vaccinology: developing vaccines in the era of genomics. Immunity 2010; 33(4): 530-41.
[http://dx.doi.org/10.1016/j.immuni.2010.09.017] [PMID: 21029963]
[95]
He Y, Xiang Z, Mobley HL. Vaxign: the first web-based vaccine design program for reverse vaccinology and applications for vaccine development. J Biomed Biotechnol 2010; 2010297505
[http://dx.doi.org/10.1155/2010/297505] [PMID: 20671958]
[96]
Ong E, Wang H, Wong MU, Seetharaman M, Valdez N, He Y. Vaxign-ML: supervised machine learning reverse vaccinology model for improved prediction of bacterial protective antigens. Bioinformatics 2020; 36(10): 3185-91.
[http://dx.doi.org/10.1093/bioinformatics/btaa119] [PMID: 32096826]
[97]
Doytchinova IA, Flower DR. VaxiJen: a server for prediction of protective antigens, tumour antigens and subunit vaccines. BMC Bioinformatics 2007; 8: 4.
[http://dx.doi.org/10.1186/1471-2105-8-4] [PMID: 17207271]
[98]
Pizza M, Scarlato V, Masignani V, et al. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science 2000; 287(5459): 1816-20.
[http://dx.doi.org/10.1126/science.287.5459.1816] [PMID: 10710308]
[99]
Tettelin H, Saunders NJ, Heidelberg J, et al. Complete genome sequence of Neisseria meningitidis serogroup B strain MC58. Science 2000; 287(5459): 1809-15.
[http://dx.doi.org/10.1126/science.287.5459.1809] [PMID: 10710307]
[100]
Watson PS, Turner DP. Clinical experience with the meningococcal B vaccine, Bexsero(®): Prospects for reducing the burden of meningococcal serogroup B disease. Vaccine 2016; 34(7): 875-80.
[http://dx.doi.org/10.1016/j.vaccine.2015.11.057] [PMID: 26686570]
[101]
Backert L, Kohlbacher O. Immunoinformatics and epitope prediction in the age of genomic medicine. Genome Med 2015; 7: 119.
[http://dx.doi.org/10.1186/s13073-015-0245-0] [PMID: 26589500]
[102]
Szolek A, Schubert B, Mohr C, Sturm M, Feldhahn M, Kohlbacher O. OptiType: precision HLA typing from next-generation sequencing data. Bioinformatics 2014; 30(23): 3310-6.
[http://dx.doi.org/10.1093/bioinformatics/btu548] [PMID: 25143287]
[103]
Cotugno N, Ruggiero A, Santilli V, et al. OMIC technologies and vaccine development: from the identification of vulnerable individuals to the formulation of invulnerable vaccines. J Immunol Res 2019; 20198732191
[http://dx.doi.org/10.1155/2019/8732191] [PMID: 31183393]
[104]
Xiang Z, Todd T, Ku KP, et al. VIOLIN: vaccine investigation and online information network. Nucleic Acids Res 2008; 36(Database issue): D923-8.
[PMID: 18025042]
[105]
Yang B, Sayers S, Xiang Z, He Y. Protegen: a web-based protective antigen database and analysis system. Nucleic Acids Res 2011; 39(Database issue): D1073-8.
[http://dx.doi.org/10.1093/nar/gkq944] [PMID: 20959289]
[106]
Sayers S, Ulysse G, Xiang Z, He Y. Vaxjo: a web-based vaccine adjuvant database and its application for analysis of vaccine adjuvants and their uses in vaccine development. J Biomed Biotechnol 2012; 2012831486
[http://dx.doi.org/10.1155/2012/831486] [PMID: 22505817]
[107]
Racz R, Chung M, Xiang Z, He Y. Systematic annotation and analysis of “virmugens”-virulence factors whose mutants can be used as live attenuated vaccines. Vaccine 2013; 31(5): 797-805.
[http://dx.doi.org/10.1016/j.vaccine.2012.11.066] [PMID: 23219434]
[108]
Sayers S, Li L, Ong E, et al. Victors: a web-based knowledge base of virulence factors in human and animal pathogens. Nucleic Acids Res 2019; 47(D1): D693-700.
[http://dx.doi.org/10.1093/nar/gky999] [PMID: 30365026]
[109]
Smith CC, Chai S, Washington AR, et al. Machine-learning prediction of tumor antigen immunogenicity in the selection of therapeutic epitopes. Cancer Immunol Res 2019; 7(10): 1591-604.
[http://dx.doi.org/10.1158/2326-6066.CIR-19-0155] [PMID: 31515258]
[110]
Ong E, Wong MU, Huffman A, He Y. COVID-19 coronavirus vaccine design using reverse vaccinology and machine learning. Front Immunol 2020; 11: 1581.
[http://dx.doi.org/10.3389/fimmu.2020.01581] [PMID: 32719684]
[111]
Ashburner M, Ball CA, Blake JA, et al. The Gene Ontology Consortium. Gene ontology: tool for the unification of biology. Nat Genet 2000; 25(1): 25-9.
[http://dx.doi.org/10.1038/75556] [PMID: 10802651]
[112]
Bandrowski A, Brinkman R, Brochhausen M, et al. The ontology for biomedical investigations. PLoS One 2016; 11(4)e0154556
[http://dx.doi.org/10.1371/journal.pone.0154556] [PMID: 27128319]
[113]
Sarntivijai S, Lin Y, Xiang Z, et al. CLO: The cell line ontology. J Biomed Semantics 2014; 5: 37.
[http://dx.doi.org/10.1186/2041-1480-5-37] [PMID: 25852852]
[114]
Hur J, Özgür A, Xiang Z, He Y. Development and application of an interaction network ontology for literature mining of vaccine-associated gene-gene interactions. J Biomed Semantics 2015; 6: 2.
[http://dx.doi.org/10.1186/2041-1480-6-2] [PMID: 25785184]
[115]
Smith B, Ashburner M, Rosse C, et al. OBI Consortium. The OBO Foundry: coordinated evolution of ontologies to support biomedical data integration. Nat Biotechnol 2007; 25(11): 1251-5.
[http://dx.doi.org/10.1038/nbt1346] [PMID: 17989687]
[116]
Lin Y, He Y. Ontology representation and analysis of vaccine formulation and administration and their effects on vaccine immune responses. J Biomed Semantics 2012; 3(1): 17.
[http://dx.doi.org/10.1186/2041-1480-3-17] [PMID: 23256535]
[117]
Ong E, Sun P, Berke K, Zheng J, Wu G, He Y. VIO: ontology classification and study of vaccine responses given various experimental and analytical conditions. BMC Bioinformatics 2019; 20(Suppl. 21): 704.
[http://dx.doi.org/10.1186/s12859-019-3194-6] [PMID: 31865910]
[118]
Lin Y, Zheng J, He Y. VICO: Ontology-based representation and integrative analysis of Vaccination Informed Consent forms. J Biomed Semantics 2016; 7: 20.
[http://dx.doi.org/10.1186/s13326-016-0062-4] [PMID: 27099700]
[119]
He Y, Sarntivijai S, Lin Y, et al. OAE: The ontology of adverse events. J Biomed Semantics 2014; 5: 29.
[http://dx.doi.org/10.1186/2041-1480-5-29] [PMID: 25093068]
[120]
Marcos E, Zhao B, He Y. The Ontology of Vaccine Adverse Events (OVAE) and its usage in representing and analyzing adverse events associated with US-licensed human vaccines. J Biomed Semantics 2013; 4(1): 40.
[http://dx.doi.org/10.1186/2041-1480-4-40] [PMID: 24279920]
[121]
Chen RT, Rastogi SC, Mullen JR, et al. The Vaccine Adverse Event Reporting System (VAERS). Vaccine 1994; 12(6): 542-50.
[http://dx.doi.org/10.1016/0264-410X(94)90315-8] [PMID: 8036829]
[122]
Sarntivijai S, Xiang Z, Shedden KA, et al. Ontology-based combinatorial comparative analysis of adverse events associated with killed and live influenza vaccines. PLoS One 2012; 7(11)e49941
[http://dx.doi.org/10.1371/journal.pone.0049941] [PMID: 23209624]
[123]
Xie J, Wang J, Li Z, Wang W, Pang Y, He Y. Ontology-based meta-analysis of animal and human adverse events associated with licensed brucellosis vaccines. Front Pharmacol 2018; 9: 503.
[http://dx.doi.org/10.3389/fphar.2018.00503] [PMID: 29867505]
[124]
Brown EG, Wood L, Wood S. The medical dictionary for regulatory activities (MedDRA). Drug Saf 1999; 20(2): 109-17.
[http://dx.doi.org/10.2165/00002018-199920020-00002] [PMID: 10082069]
[125]
Lin Y, He Y. The ontology of genetic susceptibility factors (OGSF) and its application in modeling genetic susceptibility to vaccine adverse events. J Biomed Semantics 2014; 5: 19.
[http://dx.doi.org/10.1186/2041-1480-5-19] [PMID: 24963371]
[126]
Jerne NK. The somatic generation of immune recognition. 1971. Eur J Immunol 2004; 34(5): 1234-42.
[http://dx.doi.org/10.1002/eji.200425132] [PMID: 15114656]
[127]
Civello A. On the genesis of the idiotypic network theory. J Hist Biol 2013; 46(1): 125-58.
[http://dx.doi.org/10.1007/s10739-012-9346-4] [PMID: 23207664]
[128]
Poland GA, Ovsyannikova IG, Jacobson RM, Smith DI. Heterogeneity in vaccine immune response: the role of immunogenetics and the emerging field of vaccinomics. Clin Pharmacol Ther 2007; 82(6): 653-64.
[http://dx.doi.org/10.1038/sj.clpt.6100415] [PMID: 17971814]
[129]
Poland GA, Ovsyannikova IG, Jacobson RM. Application of pharmacogenomics to vaccines. Pharmacogenomics 2009; 10(5): 837-52.
[http://dx.doi.org/10.2217/pgs.09.25] [PMID: 19450131]
[130]
He Y. Ontology-supported research on vaccine efficacy, safety and integrative biological networks. Expert Rev Vaccines 2014; 13(7): 825-41.
[http://dx.doi.org/10.1586/14760584.2014.923762] [PMID: 24909153]

Rights & Permissions Print Cite
Article Metrics
53
2
© 2024 Bentham Science Publishers | Privacy Policy